Literature DB >> 1009522

Cis-dichlorodiammineplatinum(II) in advanced bladder cancer.

A Yagoda, R C Watson, J C Gonzalez-Vitale, H Grabstald, W F Whitmore.   

Abstract

Cis-dichlorodiammineplatinum(II) (DDP) was given at a dose of 1.25 or 1.6 mg/kg to 24 patients with advanced measurable, urinary tract cancer. Eight patients (35%) achieved a partial remission and four additional patients had a minor response. There were 14 patients with epidermoid (transitional cell) bladder cancer who had had no prior chemotherapy and all eight partial responders were in this group. DDP appears to be one of the more active antineoplastic agents in bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1009522

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  22 in total

Review 1.  Systemic therapy for bladder cancer finally comes into a new age.

Authors:  Matthew Zibelman; Elizabeth R Plimack
Journal:  Future Oncol       Date:  2016-07-12       Impact factor: 3.404

Review 2.  Cis-platinum: a new anticancer agent.

Authors:  C J Williams; J M Whitehouse
Journal:  Br Med J       Date:  1979-06-23

3.  Chemotherapy in bladder cancer.

Authors: 
Journal:  Br Med J       Date:  1977-12-17

Review 4.  Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.

Authors:  Samuel A Funt; Jonathan E Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

5.  Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").

Authors:  Mayer Fishman
Journal:  Transl Androl Urol       Date:  2019-10

6.  Sodium thiosulfate fails to increase the therapeutic index of intravenously administered cis-diamminedichloroplatinum (II) in mice bearing murine and human tumors.

Authors:  S Aamdal; O Fodstad; A Pihl
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.

Authors:  Joan Carles; Cristina Suárez; Carlos Mesía; Miquel Nogué; Albert Font; Montserrat Doménech; Marta Suárez; Ignasi Tusquets; M Gallén; Joan Albanell; Xavier Fabregat
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

8.  Phase II evaluation of fractionated low and single high dose cisplatin in various tumors.

Authors:  R B Schilcher; M Wessels; N Niederle; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

9.  Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

Authors:  A H Calvert; S J Harland; D R Newell; Z H Siddik; A C Jones; T J McElwain; S Raju; E Wiltshaw; I E Smith; J M Baker; M J Peckham; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Phase-II trials in patients with urothelial tract tumors. Memorial Sloan-Kettering Cancer Center.

Authors:  A Yagoda
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.